Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
Go back to Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101| (NASDAQ: RADX) | Delayed: 0.98 -0.01 (1.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.99 | 52 Week High | $ | |||
| Open | $0.96 | 52 Week Low | $ | |||
| Day High | $1.01 | P/E | N/A | |||
| Day Low | $0.90 | EPS | $ | |||
| Volume | 14,360 | |||||



